Role of STAT3 signaling transduction pathways in cancer stem cell-associated chemoresistance
| Autor: | Kuo-Ching Mei, Po-Chang Shih |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
STAT3 Transcription Factor
0301 basic medicine Epithelial-Mesenchymal Transition Antineoplastic Agents 03 medical and health sciences Transduction (genetics) 0302 clinical medicine Cancer stem cell Neoplasms Drug Discovery Animals Humans STAT3 Gene Pharmacology biology 030104 developmental biology Stat3 signaling Drug Resistance Neoplasm 030220 oncology & carcinogenesis embryonic structures Cancer cell Neoplastic Stem Cells biology.protein STAT protein Cancer research Phosphorylation Signal Transduction |
| Zdroj: | Drug Discovery Today. 26:1450-1458 |
| ISSN: | 1359-6446 |
| DOI: | 10.1016/j.drudis.2020.11.032 |
| Popis: | Chemoresistance resulting from cancer stem cells (CSCs) and epithelial-mesenchymal transition (EMT) results in inconsistent chemotherapeutic efficacy. The co-existence of CSCs and the EMT allows cancer cells to interconvert between differentiated and stem-like states, a phenomenon known as cellular plasticity. Phosphorylated signal transducer and activator of transcription 3 (pSTAT3) has been increasingly identified as a major contributor to CSCs and the EMT, as evidenced from preclinical studies that reversed chemoresistance through STAT3 pathway inhibition. In this review, we discuss mechanisms that center on STAT3 and its target genes responsible for regulating the EMT. We also highlight the current status of clinical trials using STAT3 pathway inhibitors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect